Talanx Reports Strong Q3 Results and Raises 2026 Profit Forecast
Talanx Group reported a significant increase in third-quarter net income and raised its full-year 2026 profit guidance while providing an initial outlook for 2027.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Talanx Group reported a significant increase in third-quarter net income and raised its full-year 2026 profit guidance while providing an initial outlook for 2027.
HDI Seguros, a subsidiary of Talanx, has successfully migrated its life insurance portfolio acquired from Sompo onto the insureMO insurance middle office platform.
Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, driven by strong demand for PSMA imaging products Gozellix and Illuccix. The company received FDA approval for Pixclara for glioma imaging and announced a transformational merger with Isotope Technologies Munich (ITM) for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical company with expanded isotope production capabilities. Telix reaffirmed FY 2026 revenue guidance exceeding US$1 billion.
Telix Pharmaceuticals has partnered with Ekalia (a joint venture between IBA and Framatome) to establish dedicated U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The collaboration will install IBA's alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia, securing long-term isotope access for Telix's pipeline including TLX102-Tx for glioblastoma, while also supporting third-party programs.